Zimmer Biomet raises annual profit forecast on strong demand for medical devices

Zimmer Biomet (ZBH.N) raised its full-year adjusted profit forecast to $8.10-$8.30 per share, up from $7.90-$8.10, after exceeding second-quarter earnings and revenue estimates. This strong performance, driven by accelerating demand for hip and knee implants, a robust new product cycle including surgical robotics, and continued growth in its S.E.T. business, reflects the company's successful capture of increasing orthopedic procedure volumes fueled by an aging population.

Analysis

Zimmer Biomet Holdings (ZBH) delivered a strong second-quarter performance, exceeding analyst expectations on both revenue and earnings while raising its full-year profit guidance. The company reported Q2 revenue of $2.08 billion against estimates of $2.05 billion and an adjusted profit of $2.07 per share, surpassing the consensus of $1.98. This outperformance is driven by accelerating demand for its core hip and knee implants, which saw combined sales grow to $1.36 billion from $1.31 billion a year prior, and particularly strong growth in its sports medicine, extremities, and trauma (S.E.T.) unit, where sales surged 17.3% to $550.6 million. Management attributes this momentum to a successful new product cycle and early adoption of advancements in surgical robotics. The company's confidence is reflected in its revised full-year adjusted profit forecast, now set at $8.10 to $8.30 per share, which is significantly above the prior range and the LSEG analyst consensus of $7.97. The updated revenue growth forecast of 6.7% to 7.7% represents a tightening and a raised midpoint from the previous 5.7% to 8.2% range, indicating increased management visibility underpinned by demographic tailwinds from an aging population seeking surgical procedures.

Key Decisions for Investors

• Given the strong earnings beat and upwardly revised profit guidance that surpasses analyst consensus, investors should view these results as a positive catalyst and a validation of the company's product cycle and commercial execution.
• Monitor the sales trajectory of the S.E.T. business and commentary on surgical robotics adoption, as these high-growth areas are key drivers for sustaining momentum and margin expansion.
• Consider the revised revenue guidance, which, while raising the floor, also slightly lowers the ceiling, suggesting investors should weigh the enhanced profitability outlook against a more defined top-line growth range.